8 Feb 2019 12:00
NMC Health plc
Board Change
London, 8 February 2019: NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces that Dr Nandini Tandon has decided to step down from the Board with immediate effect to more fully focus on her other business interests.
The Nominations Committee of the Board is commencing the search for a replacement Independent Non-Executive Director to be appointed to the Board as soon as practicable and has appointed an independent external agency to assist in this search.
Mark Tompkins, Chairman of NMC Health commented:
'We would like to thank Dr. Nandini for her significant contribution to the Board over the last four and a half years of transformation and growth for NMC. We wish her well in her future endeavours.''
Investors NMC |
|
H. J. Mark Tompkins, Independent Non-Executive Joint Chairman | +44 (0)20 3205 7313 |
| |
Media: | |
FTI Consulting, London | |
Brett Pollard | +44 (0)20 3727 1000 |
FTI Consulting, Gulf | |
Shane Dolan | +971 (0)4 437 2100 |
About NMC Health
NMC the leading private healthcare operator in the GCC with an international network of hospitals across 17 countries. NMC also ranks as one of the top 3 in-vitro fertilisation ("IVF") operators globally. The Group is also a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing an aggressive international expansion program from 2016, the company now has over 34% of its licensed bed capacity in the Kingdom of Saudi Arabia (KSA), where the company has introduced long-term and multi-specialty care services. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company is set to substantially boost the Group's bed capacity in KSA, with the JV expected to be the second largest healthcare operator in the Kingdom in terms of number of beds. NMC received over 5.7m patients in 2017. The Group is also a leading UAE supplier of products and consumables across several key market segments, with the major contribution coming from healthcare related products. The Group reported revenues of US$1.6 billion for the year ended 31 December 2017.
In April 2012 NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.